- Home
- BDTX vs JYNT Comparison
BDTX vs JYNT Comparison
Compare BDTX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- JYNT
- Stock Information
- Founded
- BDTX 2014
- JYNT 2010
- Country
- BDTX United States
- JYNT United States
- Employees
- BDTX N/A
- JYNT N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- JYNT Multi-Sector Companies
- Sector
- BDTX Health Care
- JYNT Miscellaneous
- Exchange
- BDTX Nasdaq
- JYNT Nasdaq
- Market Cap
- BDTX 181.4M
- JYNT 170.3M
- IPO Year
- BDTX 2020
- JYNT 2014
- Fundamental
- Price
- BDTX $2.76
- JYNT $10.89
- Analyst Decision
- BDTX Strong Buy
- JYNT Strong Buy
- Analyst Count
- BDTX 5
- JYNT 3
- Target Price
- BDTX $13.40
- JYNT $16.33
- AVG Volume (30 Days)
- BDTX 914.3K
- JYNT 46.5K
- Earning Date
- BDTX 08-07-2025
- JYNT 08-07-2025
- Dividend Yield
- BDTX N/A
- JYNT N/A
- EPS Growth
- BDTX N/A
- JYNT N/A
- EPS
- BDTX 0.25
- JYNT N/A
- Revenue
- BDTX $70,000,000.00
- JYNT $53,449,713.00
- Revenue This Year
- BDTX N/A
- JYNT $9.48
- Revenue Next Year
- BDTX N/A
- JYNT $11.15
- P/E Ratio
- BDTX $11.03
- JYNT N/A
- Revenue Growth
- BDTX N/A
- JYNT 277.36
- 52 Week Low
- BDTX $1.20
- JYNT $9.58
- 52 Week High
- BDTX $6.75
- JYNT $13.47
- Technical
- Relative Strength Index (RSI)
- BDTX 52.31
- JYNT 44.36
- Support Level
- BDTX $2.22
- JYNT $10.46
- Resistance Level
- BDTX $2.84
- JYNT $11.26
- Average True Range (ATR)
- BDTX 0.20
- JYNT 0.39
- MACD
- BDTX -0.01
- JYNT -0.03
- Stochastic Oscillator
- BDTX 72.00
- JYNT 33.33
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.